Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Elicio Therapeutics Inc.
ELTX | US
11.49
USD-0.63
-5.20%
ELTX | US
About Elicio Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
11.49
Open
12.01
High
12.49
Low
11.17
Elicio Therapeutics Inc. a clinical-stage biotechnology company engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002 an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004 an AMP-modified CpG adjuvant a component of ELI-002 to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005 a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P) a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines adjuvants and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS INC. and changed its name to Elicio Therapeutics Inc. on September 18 2019. The company was incorporated in 2011 and is headquartered in Boston Massachusetts.
View LessELTX | US
Risk
102.8
Sharpe
0.74
Luna's Score
49/100
Recommendation
Hold
Luna says (ELTX | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
81.4%1 month
102.8%3 months
88.1%6 months
83.4%Returns
Fundamental Ratios
PE
5.18
Fwd. PE
-
Price to book
10.11
Debt to equity
-3.89
Debt to assets
0.41
Ent. to EBITDA
-2.61
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-41.00M
MarketCap
120.29M
MarketCap(USD)
120.29M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-353.02
Short ratio
2.36
Short perc.
0.45
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.38
Range1M
3.69
Range3M
4.78
Volumes: Market Activity
Rel. volume
0.87
Price X volume
1.37M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.61 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | 5.18 | 41.03 | Cheaper |
| Price to Book | 10.11 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 88.13 | - | Riskier |
| Debt to Equity | -3.89 | -1.23 | Cheaper |
| Debt to Assets | 0.41 | 0.25 | Expensive |
| Market Cap | 120.29M | - | Emerging |
